A team of AIDS researchers, including two Harvard biostatisticians, published an article in the Journal of the American Medical Association last week detailing the failures of an HIV vaccine, despite the protests of the study's sponsor.
The sponsor, Immune Response, filed a lawsuit in September for seven to ten million dollars immediately following the research team's refusal to include the company analysis of the study's results.
The suit specifically names the research team leader, James Kahn, a professor from the University of California at San Francisco (UCSF), and the UCSF regents.
While the firm maintains it should have a role in shaping the study's analysis, the scientists--whose findings indicated the HIV vaccine was a dud--said scientific freedom was their guiding principle.
Kahn headed the study along with Dr. Kenneth Mayer, an AIDS researcher at Brown, and two Harvard biostatisticians, Professor of Biostatistics Stephen Lagakos and Deborah Weng Cheng, a biostatistician in the Center for Biostatistics in AIDS Research.
Immune Response, a California-based biotech company, commissioned the study in 1995 to use 2,500 HIV patients as a test study for the HIV vaccine, Remune.
They tested the ability of Remune to boost the immune response of HIV-infected people by reducing the patient's viral load because "it showed some activity in the lab," Cheng said.
However, by May 1999 the patients receiving Remune in addition to standard HIV treatment were faring no better than the control group, causing the Data Safety Monitoring Board and Immune Response to agree to stop the study, Kahn said.
Upon presentation of their paper describing Remune's ineffectiveness, Kahn says it was clear they "did not present an analysis that the sponsor wanted."
"They wanted the right to review all manuscripts," Kahn said of Immune Response, which the researchers refused because it was "clear it was a way to delay publication."
Dr. Ronald B. Moss, vice president of medical and scientific affairs for Immune Response, refused to comment. Calls to the public relations office were not returned.
Both Kahn and Cheng stressed their duty to the patients who participated in the Remune study in publishing their negative data.
"Patients involved in research treatment should be involved with the outcome," Cheng said.
For the researchers, the Immune Response lawsuit endangers the larger issue of scientific freedom and places a conditional value on scientific research.
"They're sort of like bullies in a sandbox--they take their toys and escape," Kahn said of Immune Response.
But the scientists said they are not concerned about the future of scientific research.
"So far my colleagues have been very supportive," Kahn says, "I just hope that people will not wait for sanitized results."
Lagakos is currently in Japan and could not be reached for comment.
Monday, November 7, 2011
Immune Response and Orchestra stock manipulation
The price of Orchestra Therapeutics stays at 0.0035. Twice in the past few weeks including last week I purchased shares in of the stock at the market price which was .01 cents a share bringing the last purchase price up to .01 cents on the financial board. Both times there was an immediate trade of over 300 shares at 0.0035 bringing the price of the stock back down. Could it be that someone is purposely trying to manipulate the price of the stock to keep it below .01 cents a share. I mean why would someone offer to sell at 0.0035 when the last trade was higher and why would it always be the same price and the same amount of stock being exchanged. I wounder if someone is not deliberately trying to keep the price down at 0.0035 Does anyone have a guess as to what reason they might have?
Tuesday, October 18, 2011
Wednesday, October 5, 2011
Immune Response BioPharma Stock
I purchased another 3000 shares of Orchestra Theraputic (OCHTQ.PK) today. It is important that stock holders in Immune Response/Orchestra Therap keep the stock active to help protect our rights and to make sure it stays active on the trading boards.
Monday, September 26, 2011
Immune Response Biopharma and Rheumatoid Arthritis
I have a sister and a best friend who suffer from Rheumatoid arthritis. It is the reason I invested in the company to begin with. I wonder if David Buswell and Immune Response Biopharma "found" that research abandoned somewhere also and now say it is theirs.
"The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received United States Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, RAVAX(TM). The recently issued patent has specific claims covering immunization utilizing DNA vaccines that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key "superantigen" protein sequences from the Vbeta 3, Vbeta 14 and Vbeta 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis. The Company believes that vaccination with RAVAX may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease. "This recent issuance is a key patent in that it extends previous coverage related to the delivery and composition of RAVAX to now include DNA vaccines in addition to peptide vaccines," said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. "DNA vaccination is proving to be an effective method of inducing immunity against a number of human diseases. The issuance of this patent to include DNA vaccination for our peptide vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research." The Company previously announced that it was issued U.S. patent number 6,090,387 for vaccinating with T cell receptor peptides on August 9, 2000. Several autoimmune disorders, including rheumatoid arthritis, psoriasis and multiple sclerosis, are thought to result in part from the proliferation of "autoreactive pathogenic T cells," immune cells that incorrectly identify the body's own cells as foreign and destroy them. The Immune Response Corporation has completed two Phase II clinical trials in rheumatoid arthritis using their proprietary immune-based therapy based on TCR peptide vaccines. In a phase IIb trial of 340 rheumatoid arthritis patients, RAVAX demonstrated safety and tolerability, and suggested a statistically significant treatment effect at one time point after the third injection using criteria established by the American College of Rheumatology (ACR 20). The ACR 20 criteria require an improvement in tender and swollen joint counts of at least 20% from baseline, along with improvement in three of five other disease-related criteria. To date, no clinical studies have been initiated utilizing the DNA vaccination approach."
"The Immune Response Corporation (Nasdaq: IMNR) announced today that it has received United States Patent Number 6,207,645 expanding coverage relating to its immune-based therapy for rheumatoid arthritis, RAVAX(TM). The recently issued patent has specific claims covering immunization utilizing DNA vaccines that are designed to synthesize the T cell receptor (TCR) Vbeta specific peptides in situ, in contrast to immunizing directly with the TCR peptides themselves. The patent also includes specific claims for DNA vaccines encoding key "superantigen" protein sequences from the Vbeta 3, Vbeta 14 and Vbeta 17 regions of the TCR present on the surface of these pathogenic T cells thought to be associated with rheumatoid arthritis. The Company believes that vaccination with RAVAX may inhibit the disease-associated T cells that cause rheumatoid arthritis, and prevent further damage in patients suffering from the disease. "This recent issuance is a key patent in that it extends previous coverage related to the delivery and composition of RAVAX to now include DNA vaccines in addition to peptide vaccines," said Richard Bartholomew, Ph.D., Executive Director of Research Operations for The Immune Response Corporation. "DNA vaccination is proving to be an effective method of inducing immunity against a number of human diseases. The issuance of this patent to include DNA vaccination for our peptide vaccine program serves to further strengthen our intellectual property position in the field of T cell receptor vaccine research." The Company previously announced that it was issued U.S. patent number 6,090,387 for vaccinating with T cell receptor peptides on August 9, 2000. Several autoimmune disorders, including rheumatoid arthritis, psoriasis and multiple sclerosis, are thought to result in part from the proliferation of "autoreactive pathogenic T cells," immune cells that incorrectly identify the body's own cells as foreign and destroy them. The Immune Response Corporation has completed two Phase II clinical trials in rheumatoid arthritis using their proprietary immune-based therapy based on TCR peptide vaccines. In a phase IIb trial of 340 rheumatoid arthritis patients, RAVAX demonstrated safety and tolerability, and suggested a statistically significant treatment effect at one time point after the third injection using criteria established by the American College of Rheumatology (ACR 20). The ACR 20 criteria require an improvement in tender and swollen joint counts of at least 20% from baseline, along with improvement in three of five other disease-related criteria. To date, no clinical studies have been initiated utilizing the DNA vaccination approach."
Wednesday, August 31, 2011
Immune Response BioPharma and investors
Immune Response BioPharma's David Buswell made some interesting comments recently in regards to House Resolution 1179 (H. Res 1179) saying that it was wasted taxpayer dollars. He seems to take the moral high ground in the following statements.
“These are really wicked bad people and want to waste your taxpayer dollars on obsolete and junk science. Everyone knows the way to defeat a virus is through the weakened vaccine. They are terrified of my efforts to get REMUNE approved and have gone so far as to trick me on to a conference call and both of them yelled at me for over two hours. These people are crazy and just want to go on needless conferences wasting your taxpayer dollars and junk science and toxic solutions. I pray that God takes action against these evil people”
“They have done their best to discredit my efforts and are trying their best to derail patients from getting the REMUNE vaccine. REMUNE can solve the majority of the HIV/AIDS issues. And I am not afraid of these people they are cowards who do not want a real solution to the pandemic. They just want to continue their lifestyles of wasting taxpayer dollars, and big pharma too has no reason to want REMUNE approved they lose billions of dollars. I restarted Immune Response to save lives I receive no salary. The IP and trademarks were abandoned the company was dissolved and I restarted this company because I believe the science is sound and I won’t be pushed around by wall St.. or these evil people. I am not afraid of cowards”
I would suggest that the best way to advance the research conducted by Immune Response Corportation and Orchestra Therapeutics (OCHT) is to honor the shareholders of OCHT which still trades and whose investors still have rights. The people in charge of managing IMNR and OCHT might have been dishonest, but their investors were hard working people who invested in what they thought was an honestly operated company. Immune Response BioPharma should recognize the shareholders in OCHT by giving them stock in their new company or else paying them compensation for their investments which created the research David Buswell is now trying to bring to market. If you are going to take research from a company that had a reputation for trying to prevent negative test results from being printed not to mention the management disaster that was Immune Response/Orchestra then you better start out on the right foot and do it in a fair and honest manner from day one.
Saturday, August 13, 2011
Latest news release from Immune Response BioPharma
Despite what the Immune Response BioPharma says about the Immune Response/Orchestra Thera research the last releases from the company certainly didn't sound good.
"CARLSBAD, Calif., July 17, Orchestra
Therapeutics, Inc. (OTC Bulletin Board: OCHT) announced today the
discontinuation of its HIV Vaccine Development Program. Analysis of data
from 70 patients who completed a 52 weeks clinical trial in Europe and
Canada did not show a clear advantage of Orchestra Therapeutics' second
generation HIV vaccine, IR103, over its original whole-killed HIV vaccine,
REMUNE(R). Furthermore, although interim analysis of patients in this trial
at 36 weeks suggested a trend toward stabilization of CD4+ counts in HAART
naive patients vaccinated with REMUNE(R) or IR103, this trend was not
observed at week 52."
"CARLSBAD, Calif., July 17, Orchestra
Therapeutics, Inc. (OTC Bulletin Board: OCHT) announced today the
discontinuation of its HIV Vaccine Development Program. Analysis of data
from 70 patients who completed a 52 weeks clinical trial in Europe and
Canada did not show a clear advantage of Orchestra Therapeutics' second
generation HIV vaccine, IR103, over its original whole-killed HIV vaccine,
REMUNE(R). Furthermore, although interim analysis of patients in this trial
at 36 weeks suggested a trend toward stabilization of CD4+ counts in HAART
naive patients vaccinated with REMUNE(R) or IR103, this trend was not
observed at week 52."
Monday, August 8, 2011
News Release from Immune Response BioPharma
The latest news release from Immune Response BioPharma includes the following statement, "I believe we are close to receiving funding and support from a prominent businessman and we will move forward building a dynamic pharmaceutical company to save lives. Those who wait to partner with IRBP and wait to collaborate including big pharma will lose out” Mr. Buswell COO.
Wouldn't it be interesting if the prominent businessman and financing were to come from Kevin Kimberlin and the good folks at Spencer Trask. The same folks who started Immune Response Corporation later Orchestra Therapeutics and then manipulated the stock into the ground, purchased all the research property rights and then abandoned them so that a new company called Immune Response BioPharma could reform using the same research and technology leaving all the old investors behind.
Wouldn't it be interesting if the prominent businessman and financing were to come from Kevin Kimberlin and the good folks at Spencer Trask. The same folks who started Immune Response Corporation later Orchestra Therapeutics and then manipulated the stock into the ground, purchased all the research property rights and then abandoned them so that a new company called Immune Response BioPharma could reform using the same research and technology leaving all the old investors behind.
Monday, July 25, 2011
David Buswell
The following statements were released July 23, 2011 by David Buswell COO of Immune Response BioPharma.
"We are proud of the work we have done in such a short period of time. There remains much outstanding work to do. IRBP has a great pipeline and we have multiple goals on shot with our NeuroVax MS Vaccine the technology, with applications of the drug in RA with our drug RAVAX. We believe REMUNE holds the safest and most effective treatment option for HIV/AIDS the HAART drugs are just plain toxic and poisonous, I am committed to saving lives and getting patients the vaccine” Mr. Buswell COO.
“REMUNE is a winner hands down and see the vaccine as the gold standard of treatment, eventually 90% market share , as soon as we have clarity on CGMP’s manufacturing we will press forward on an NDA for REMUNE. I believe we are close to receiving funding and support from a prominent businessman and we will move forward building a dynamic pharmaceutical company to save lives. Those who wait to partner with IRBP and wait to collaborate including big pharma will lose out” Mr. Buswell COO."
It is interesting that he was able to take research from Immune Reponse Corporation aka Orchestra
"We are proud of the work we have done in such a short period of time. There remains much outstanding work to do. IRBP has a great pipeline and we have multiple goals on shot with our NeuroVax MS Vaccine the technology, with applications of the drug in RA with our drug RAVAX. We believe REMUNE holds the safest and most effective treatment option for HIV/AIDS the HAART drugs are just plain toxic and poisonous, I am committed to saving lives and getting patients the vaccine” Mr. Buswell COO.
“REMUNE is a winner hands down and see the vaccine as the gold standard of treatment, eventually 90% market share , as soon as we have clarity on CGMP’s manufacturing we will press forward on an NDA for REMUNE. I believe we are close to receiving funding and support from a prominent businessman and we will move forward building a dynamic pharmaceutical company to save lives. Those who wait to partner with IRBP and wait to collaborate including big pharma will lose out” Mr. Buswell COO."
It is interesting that he was able to take research from Immune Reponse Corporation aka Orchestra
Therapeutics and now offers the "gold standard" as they put it. Immune/Orchestra continually returned failed test results using the same research and science to the point that Pfizer gave up and abandoned them. The investors lost all their money, the employees all left, the compnay was unable to obtain any financing or grants and finally it was forced into bankruptcy. Now along comes Mr. Buswell and he declares the research a "gold mine." If it was "gold" why did it not attract investors before? Why were the test results from clinical trials always failures? Why did reputable researchers and scientists accuse the company of trying to manipultate and hide poor test result findings? Why could the company not obtain any grant funding? Why did Wall Street and its investors abandon the company?
Why did Kevin Kimberlin and Spencer Trask continue to give the company money in exchange for the intellectual property rights to the research right up to the moment the company filed bankruptcy? How did David Buswell and Immune Response BioPharma obtain the research files, papers, digital data, clinical results, and patient records?
We would all like to see patients cured, but we would also like to see the business behind it done in a proper, legal, and morally acceptable manner. It should not be done through manipulation in order that the original investors are cheated and abandoned and all the profits go to the insiders who were pulling the strings on the demise of Immune Response Corporation and Orchestra Therapeutics.
Tuesday, July 12, 2011
Kevin Kimberlin, Spencer Trask, and David Buswell, Immune Response
I have writen to Immune Response Biopharma and Spencer Trask several times asking if Spencer Trask or Kevin Kimberlin were involved in the financial support or creation of the Immune Response Biopharma company which is now laying claims to the research financed by the investors of Immune Response Corportation and Orchestra Therapeutics, Inc. The only response I have received back is threatening letters from David Buswell. They refuse to say if Kevin Kimberlin and Spencer Trask is involved in Immune Response BioPharma or not. I wonder what to make of that.
Wednesday, July 6, 2011
Spencer Trask
I sent E-mails to both Immune Response BioPharma and Spencer Trask asking if Spencer Trask or Kevin Kimberlin were involved in the financing or managerment of Immune Response BioPharma. Hopefully I will receive a simple honest response.
Dear Sir or Madam:
It is my understanding that your company is claiming to now own the rights to the research conducted over the past twenty plus years by the Immune Response and Orchestra Therapeutic Corporations. Kevin Kimberlin and Spencer Trask were owners in these companies and purchased much of the intellectual property rights. Obviously, for those rights to have been abandoned legally there could be no involvement in Immune Response BioPharma by either Mr. Kimberlin or Spencer Trask as that would simply mean that they helped finance and start a new company under a new name and simply transferred the research rights in order to abandon the previous companies investors and make more profit for themselves.
I have a simple question. Is either Kevin Kimberlin or Spencer Trask involved in the financing or operation of Immune Response BioPharma?
Sincerely,
Joel Reese
Dear Sir or Madam:
It is my understanding that your company is claiming to now own the rights to the research conducted over the past twenty plus years by the Immune Response and Orchestra Therapeutic Corporations. Kevin Kimberlin and Spencer Trask were owners in these companies and purchased much of the intellectual property rights. Obviously, for those rights to have been abandoned legally there could be no involvement in Immune Response BioPharma by either Mr. Kimberlin or Spencer Trask as that would simply mean that they helped finance and start a new company under a new name and simply transferred the research rights in order to abandon the previous companies investors and make more profit for themselves.
I have a simple question. Is either Kevin Kimberlin or Spencer Trask involved in the financing or operation of Immune Response BioPharma?
Sincerely,
Joel Reese
Thursday, June 30, 2011
Immune Response BioPharma
The people at Immune Response BioPharma have sent a letter to the FDA trying to get approval of the Remune vaccine developed by Immune Response aka Orchestra. In the letter they refer to the people at Immune Response by saying, "while the former management was unethical and irresponsible and cared only about their wallets and stock price." This is a true statement. Thousands of honest investors lost all their money due to the false statements and research conducted by Kevin Kimberlin's and Spencer Trask's company. My question is why would the FDA approve anything based on the research results provided by people who were "unethical and irresponsible." I mean lying to investors and trying to manipulate lap test results were what Immune Response was known for. The FDA and future investors would be fools to trust any of the Immune Response's research data. If they believe in the science they are going to have to start from scratch and repeat everything with reputable scientists and doctors administering the clinical trials and then allow for independent peer review from their fellow professionals in the field.
Wednesday, June 29, 2011
Immune Response class action lawsuit
Immune Response was known for releasing misleading reports about their research results and their chances for approval. This finally resulted in a lawsuit. Despite the suit almost all the investors in Immune Response lost their investment.
CARLSBAD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- The Immune Response Corporation (BULLETIN BOARD: IMNR) announced today that the Company has reached an agreement with class counsel to settle the consolidated federal securities law class action litigation filed against the Company in 2001, as well as the related California state-court derivative lawsuit, without admitting to any wrongdoing, fault or liability. The settlements also include Company directors and officers who were named in the lawsuits.
The class action settlement, for approximately $9.6 million, will have no effect on the Company's operations, cash flow or financial position, as it is within insurance limits. The settlement is conditioned on notice to the class members and court approval. The preliminary settlement approval hearing is scheduled to occur on December 4, 2006.
The shareholder derivative complaint was filed on July 5, 2005 against certain of the Company's current and former officers and directors. The Company was also named as a nominal defendant in the complaint.
The $0.25 million settlement for the California state-court derivative lawsuit would also be funded entirely by the Company's insurers. As anticipated by an agreement in principle for the settlement, the Company will also agree to adopt certain corporate governance requirements. The definitive state-court settlement agreement is conditioned on court approval and must be filed with the court by November 20, 2006. The settlement hearing is scheduled to occur on November 27, 2006.
About The Immune Response Corporation
The Immune Response Corporation (BULLETIN BOARD: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of multiple sclerosis (MS) and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune(R), the Company's first generation HIV product candidate. The federal class action litigation was based on the Company's reporting of results from one of those clinical studies of Remune(R). IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time.
CARLSBAD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- The Immune Response Corporation (BULLETIN BOARD: IMNR) announced today that the Company has reached an agreement with class counsel to settle the consolidated federal securities law class action litigation filed against the Company in 2001, as well as the related California state-court derivative lawsuit, without admitting to any wrongdoing, fault or liability. The settlements also include Company directors and officers who were named in the lawsuits.
The class action settlement, for approximately $9.6 million, will have no effect on the Company's operations, cash flow or financial position, as it is within insurance limits. The settlement is conditioned on notice to the class members and court approval. The preliminary settlement approval hearing is scheduled to occur on December 4, 2006.
The shareholder derivative complaint was filed on July 5, 2005 against certain of the Company's current and former officers and directors. The Company was also named as a nominal defendant in the complaint.
The $0.25 million settlement for the California state-court derivative lawsuit would also be funded entirely by the Company's insurers. As anticipated by an agreement in principle for the settlement, the Company will also agree to adopt certain corporate governance requirements. The definitive state-court settlement agreement is conditioned on court approval and must be filed with the court by November 20, 2006. The settlement hearing is scheduled to occur on November 27, 2006.
About The Immune Response Corporation
The Immune Response Corporation (BULLETIN BOARD: IMNR) is an immuno-pharmaceutical company focused on developing products to treat autoimmune and infectious diseases. The Company's lead immune-based therapeutic product candidates are NeuroVax(TM) for the treatment of multiple sclerosis (MS) and IR103 for the treatment of HIV infection. Both of these therapies are in Phase II clinical development and are designed to stimulate pathogen-specific immune responses aimed at slowing or halting the rate of disease progression.
NeuroVax(TM), which is based on the Company's patented T-cell receptor (TCR) peptide vaccine technology, has shown potential clinical value in the treatment of relapsing forms of MS. NeuroVax(TM) has been shown to stimulate strong, disease-specific cell-mediated immunity in nearly all patients treated and appears to work by enhancing levels of FOXP3+ Treg cells that are able to down regulate the activity of pathogenic T-cells that cause MS. Increasing scientific findings have associated diminished levels of FOXP3+ Treg cell responses with the pathogenesis and progression of MS and other autoimmune diseases such as rheumatoid arthritis (RA), psoriasis and Crohn's disease. In addition to MS, the Company has open Investigational New Drug Applications (IND) with the FDA for clinical evaluation of TCR peptide-based immune-based therapies for RA and psoriasis.
IR103 is based on the Company's patented, whole-inactivated virus technology, co-invented by Dr. Jonas Salk and indicated to be safe and immunogenic in extensive clinical studies of Remune(R), the Company's first generation HIV product candidate. The federal class action litigation was based on the Company's reporting of results from one of those clinical studies of Remune(R). IR103 is a more potent formulation that combines its whole-inactivated antigen with a synthetic Toll-like receptor (TLR-9) agonist to create enhanced HIV-specific immune responses. The Company is currently testing IR103 in two Phase II clinical studies as a first-line treatment for drug-naive HIV-infected individuals not yet eligible for antiretroviral therapy according to current medical guidelines.
NeuroVax(TM) and IR103 are in clinical development by The Immune Response Corporation and are not approved by any regulatory agencies in any country at this time.
Monday, June 27, 2011
Immune Response Test Results
The following article appeared Nov. 7, 2000 concerning research results from Immune Response.
Sunday, June 26, 2011
Orchestra
I am keeping this blog in an attempt to make people aware of the connection between Immune Response Corp. and Orchestra Thera and Immune Response BioPharma and to hopefully bring attention to the FTC and major financial and investment publications of what happened to the investors who financed the research that David Buswell and Immune Response BioPharma are now trying to market. I also would like to discover if there is a connection between Immune Response BioPharma and Kevin Kimberlin and Spencer Trask and if what Immune Response BioPharma is attempting to do is legal and morally fair to the investors of Immune Response/Orchestra.
Thursday, June 23, 2011
Kevin Kimberlin
I finally received a response back from an Eric Swanson at Immune Response Biophrma. He said the following:
"Per your note to Mr. Buswell, it's my understanding you have issues relating to his medical and business efforts. While I'm not a brankruptcy expert, I believe the science he has embraced was abandoned by the parties you mentioned in your email. It seems to me he's trying to make good on something that was left to the trash collectors."
He also went on to say,
"it is my understanding accredited investors will perhaps have an opportunity to participate in an Immune Response Biopharma Private Offering or Initial Public Offering of shares."
The company's website says,
"Dividends: The Company plans to pay regular dividends Annual $1.00 per share dividend beginning on December 25th 2011, and quarterly dividends of $.25c per share on March 30th 2012, June 30th 2012, September 30th 2012, and December 25th 2012.
Partnering out manufacturing and drug development the company intends to become a royalty generating income producing company."
I guess I am confused. Immune Reponse/Orchestra could not get anyone to partner with them nor invest in the company nor could they obtain any grant money to help stay in business. The entire scientific community said the company's test trails were fatally flawed and that their approach was outdated and basically a waste of time. The stock price dropped to below a penny a share and the company had to file Chapter 7 due to lack of funding and investment.
Now this Buswell comes along and as Stewart says he pulls the research papers from Immune Response/Orchestra out of the trash barrel and now he's going to form a new company, start paying dividends, partner with other companies and go public with an IPO for accredited investors only.
Is he running a con on ignorant investors or did Kevin Kimberlin and Spencer Trask con the rest of the investors in Immune Response/Orchestra out of their money and property rights?
Where is Buswell getting his financing from? Could it be Kevin Kimberlin and Spencer Trask or behind him?
"Per your note to Mr. Buswell, it's my understanding you have issues relating to his medical and business efforts. While I'm not a brankruptcy expert, I believe the science he has embraced was abandoned by the parties you mentioned in your email. It seems to me he's trying to make good on something that was left to the trash collectors."
He also went on to say,
"it is my understanding accredited investors will perhaps have an opportunity to participate in an Immune Response Biopharma Private Offering or Initial Public Offering of shares."
The company's website says,
"Dividends: The Company plans to pay regular dividends Annual $1.00 per share dividend beginning on December 25th 2011, and quarterly dividends of $.25c per share on March 30th 2012, June 30th 2012, September 30th 2012, and December 25th 2012.
Partnering out manufacturing and drug development the company intends to become a royalty generating income producing company."
I guess I am confused. Immune Reponse/Orchestra could not get anyone to partner with them nor invest in the company nor could they obtain any grant money to help stay in business. The entire scientific community said the company's test trails were fatally flawed and that their approach was outdated and basically a waste of time. The stock price dropped to below a penny a share and the company had to file Chapter 7 due to lack of funding and investment.
Now this Buswell comes along and as Stewart says he pulls the research papers from Immune Response/Orchestra out of the trash barrel and now he's going to form a new company, start paying dividends, partner with other companies and go public with an IPO for accredited investors only.
Is he running a con on ignorant investors or did Kevin Kimberlin and Spencer Trask con the rest of the investors in Immune Response/Orchestra out of their money and property rights?
Where is Buswell getting his financing from? Could it be Kevin Kimberlin and Spencer Trask or behind him?
Tuesday, June 21, 2011
David Buswell and Immune Response
The following was a third response I received from the compnay after contacting them and asking if they planned on compensating the investors in Immune Response and Orchestra who financed the research Immune Response BioPharma is attempting to market.
RE: Cease & Desist Order Multiple Violations
You have violated the Cease & Desist order twice, i am afraid you will have to be blocked from Microsoft and your IP domain address is being reported to the proper authorities, and multiple criminal complaints lodged against you with state and federal agencies for repeated violations of the rule of law, please get necessary help mental and counseling and medication to help you with your illegal activities, this will not be tolerated and the courst system will be notified of your harrassment, and illegal activities including the, DOJ, FBI, U.S. Postal Inspector, North Carolina State Police and Statesville, NC Local Police for your blackmailing, extortion, and attempting to obtaint money and securities under false pretences violations of federal and state laws, while this is unfortunate Immune Response BioPharma is forced to protect itself from financial terrorisim you have victimized our new company from. I demand you obey the Cease & Desist Order from 2/24/2011 and obey the rule of law and cease your criminal activities. Immune Response BioPharma will use and seek all available avenues of civil and criminal law to end your blackmailing and extortion attempts.
Sincerely,
Immune Resonse BioPharma Legal Department
RE: Cease & Desist Order Multiple Violations
You have violated the Cease & Desist order twice, i am afraid you will have to be blocked from Microsoft and your IP domain address is being reported to the proper authorities, and multiple criminal complaints lodged against you with state and federal agencies for repeated violations of the rule of law, please get necessary help mental and counseling and medication to help you with your illegal activities, this will not be tolerated and the courst system will be notified of your harrassment, and illegal activities including the, DOJ, FBI, U.S. Postal Inspector, North Carolina State Police and Statesville, NC Local Police for your blackmailing, extortion, and attempting to obtaint money and securities under false pretences violations of federal and state laws, while this is unfortunate Immune Response BioPharma is forced to protect itself from financial terrorisim you have victimized our new company from. I demand you obey the Cease & Desist Order from 2/24/2011 and obey the rule of law and cease your criminal activities. Immune Response BioPharma will use and seek all available avenues of civil and criminal law to end your blackmailing and extortion attempts.
Sincerely,
Immune Resonse BioPharma Legal Department
Monday, June 20, 2011
David Buswell and Immune Response BioPharma
The following was the second response I received from David Buswell. I found it rather a strange response considering I did not make threats and only asked questions and expressed concern as an investor in Immune Response and Orchestra Thera (OCHTQ.PK).
This is the 2nd response from the new Immune Response and David Buswell:
From: david buswell <info@immuneresponsebiopharma.com
RE:Violations of & Desist Order 2/24/2011
You were warned not to violate the Cease & Desist Order by doing so and further actions constitute a violation and Immune Response BioPharma demands you obey and comply with the order, you have left the company with no choice but to forward your threathening emails to the authoritities for a criminal complaint against you,
for harrassment, fraud, blackmail, conspiracy, collusion, business interference, financial terrorism, your continued actions are disturbing and you should get some mental help for your problems you will be held accountable, we have no position and no intentions with regard to your garbage bankrupt defunct stock ocht/imnr it is pure trash like your emails, off to the FBI they go, you need help and are a loser who is attempting to gain financial compensation from our company through fraudulent means, blackmail, intimidation, harrassment, and repeated.
Finally get through your small brain that Immune Response BioPharma has no affiliation or connection is a brand new company while the name maybe similiar in some respects it has nothing to do with your defunct organization, and will not bow down to your blackmail demands for compensation, with you or with your bad stock investments and personal misfortunes and errors, mistakes in your life. Again, all IP has been abandoned and is Public Domain your threats are meaningless and have no merit and are a bunch of hotair, you need to get help or some medication for your issues which appear to be very serious in nature, you will only cause yourself embarrassment to your family and friends with your continued actions and possibly jail time for Interstate Commerce Fraud Federal Violations use of Mail and Wire Fraud, attempting to obtain money under false pretences, the U.S. Postal Inspectors office will be notified, your IP address will be obtained from our provider Microsoft, all emails from hospitalave Yahoo screename are being collected and turned over to the authorities for a criminal complaint and possible indictment now, you should think very seriously about obeying the rule of law, and obey the rule of law and the Cease & Desist Order. Feel free to contact any class action attorney and should they begin to harrass and make illegal unmeritied threats and demands they too willbe held accountable for a criminal complaint of fraud and business interference. Again please do not contact Immune Response BioPharma ever again.
Sincereley,
Immune Response BioPharma Legal Department
This is the 2nd response from the new Immune Response and David Buswell:
From: david buswell <info@immuneresponsebiopharma.com
RE:Violations of & Desist Order 2/24/2011
You were warned not to violate the Cease & Desist Order by doing so and further actions constitute a violation and Immune Response BioPharma demands you obey and comply with the order, you have left the company with no choice but to forward your threathening emails to the authoritities for a criminal complaint against you,
for harrassment, fraud, blackmail, conspiracy, collusion, business interference, financial terrorism, your continued actions are disturbing and you should get some mental help for your problems you will be held accountable, we have no position and no intentions with regard to your garbage bankrupt defunct stock ocht/imnr it is pure trash like your emails, off to the FBI they go, you need help and are a loser who is attempting to gain financial compensation from our company through fraudulent means, blackmail, intimidation, harrassment, and repeated.
Finally get through your small brain that Immune Response BioPharma has no affiliation or connection is a brand new company while the name maybe similiar in some respects it has nothing to do with your defunct organization, and will not bow down to your blackmail demands for compensation, with you or with your bad stock investments and personal misfortunes and errors, mistakes in your life. Again, all IP has been abandoned and is Public Domain your threats are meaningless and have no merit and are a bunch of hotair, you need to get help or some medication for your issues which appear to be very serious in nature, you will only cause yourself embarrassment to your family and friends with your continued actions and possibly jail time for Interstate Commerce Fraud Federal Violations use of Mail and Wire Fraud, attempting to obtain money under false pretences, the U.S. Postal Inspectors office will be notified, your IP address will be obtained from our provider Microsoft, all emails from hospitalave Yahoo screename are being collected and turned over to the authorities for a criminal complaint and possible indictment now, you should think very seriously about obeying the rule of law, and obey the rule of law and the Cease & Desist Order. Feel free to contact any class action attorney and should they begin to harrass and make illegal unmeritied threats and demands they too willbe held accountable for a criminal complaint of fraud and business interference. Again please do not contact Immune Response BioPharma ever again.
Sincereley,
Immune Response BioPharma Legal Department
David Buswell and Immune Response BioPharma
I wrote to David Buswell and Immune Response BioPharma in February asking if they were receiving financial support from Kevin Kimberlin and Spencer Trask. They refused to answer the question and instead sent the following:
I sent an E-mail asking if the Immune Response BioPharma company was using research from the Orchestra Therap, (OCHT) or Immune Response (IMNR) Corp as it was previously known. This is the response I received.
RE: Cease & Desist Order 2/24/2011
Thank-you for your interest, Immune Response BioPharma has no connection with defunct Orchestra Therapeutics and no legal liability with that company i see that that stock still is trading i would consult your tax preparer or accountant to assist you with your ownership of that company, unfortunately our company has no affiliation with that organization and can not offer advice or guidance on your situation. In the interest of saving lives the new company has been formed with saving lives and helping advance science at this time has no publicly traded securities and has no immediate plans to issue any securities nor has any for sale, nor any obligation to any defunct or bankrupt company nor its shareholders. Furthemore has no compensation to offer you as the company has no affiliation with you, and no plans to compensate anyone with regards to a bankrupt company. While this may not be the answer you-re seeking i would refer you to the USPTO.GOV and abandoned patents and trademarks and public domain of those IP and rights once they become legally abandoned or used after certain periods of time.
I would ask you to respect the rule of law and cease and desist from contacting, harassing, interference of business, fraud, manipulation, slander, defamation, illegal activities, written or oral communication threathening, harming, cyber attacks, physical or oral or via mail any blackmail or greenmail activities or otherwise prohibited illegal activities against Immune Response BioPharma or its employees, founders or members in any shape form or fashion will be deemed as hostile acts and reported to the proper authorities. Immune Respone BioPharma is a peaceful company only seeking to save lives and has its own pipeline of life saving drugs and will act responsibly by developing those therapeutic treatments in the of mankind. Should you continue with your course of actions it will become a criminal matter which the proper authorities will be notified, at this time Immune Response BioPharma will not pursue any legal actions but cautions you to refrain from further activities that would otherwise violate the rule of law. Mr. Reese make no mistake you will be held accountable should you continue to harrass, impede, threathen, blackmail, interfere with our business and notify the Department of Justice and the FBI should you send more harrassing emails. Please Cease & Desist as of 2/24/2011 your activities and contact with Immune Response BioPharma, should you violate this order appropriate legal action will be taken. Immune Response BioPharma will use any and all legal avenues civil and criminal to halt any violations of this order.
Sincerely, Immune Response BioPharma Legal Department
I sent an E-mail asking if the Immune Response BioPharma company was using research from the Orchestra Therap, (OCHT) or Immune Response (IMNR) Corp as it was previously known. This is the response I received.
RE: Cease & Desist Order 2/24/2011
Thank-you for your interest, Immune Response BioPharma has no connection with defunct Orchestra Therapeutics and no legal liability with that company i see that that stock still is trading i would consult your tax preparer or accountant to assist you with your ownership of that company, unfortunately our company has no affiliation with that organization and can not offer advice or guidance on your situation. In the interest of saving lives the new company has been formed with saving lives and helping advance science at this time has no publicly traded securities and has no immediate plans to issue any securities nor has any for sale, nor any obligation to any defunct or bankrupt company nor its shareholders. Furthemore has no compensation to offer you as the company has no affiliation with you, and no plans to compensate anyone with regards to a bankrupt company. While this may not be the answer you-re seeking i would refer you to the USPTO.GOV and abandoned patents and trademarks and public domain of those IP and rights once they become legally abandoned or used after certain periods of time.
I would ask you to respect the rule of law and cease and desist from contacting, harassing, interference of business, fraud, manipulation, slander, defamation, illegal activities, written or oral communication threathening, harming, cyber attacks, physical or oral or via mail any blackmail or greenmail activities or otherwise prohibited illegal activities against Immune Response BioPharma or its employees, founders or members in any shape form or fashion will be deemed as hostile acts and reported to the proper authorities. Immune Respone BioPharma is a peaceful company only seeking to save lives and has its own pipeline of life saving drugs and will act responsibly by developing those therapeutic treatments in the of mankind. Should you continue with your course of actions it will become a criminal matter which the proper authorities will be notified, at this time Immune Response BioPharma will not pursue any legal actions but cautions you to refrain from further activities that would otherwise violate the rule of law. Mr. Reese make no mistake you will be held accountable should you continue to harrass, impede, threathen, blackmail, interfere with our business and notify the Department of Justice and the FBI should you send more harrassing emails. Please Cease & Desist as of 2/24/2011 your activities and contact with Immune Response BioPharma, should you violate this order appropriate legal action will be taken. Immune Response BioPharma will use any and all legal avenues civil and criminal to halt any violations of this order.
Sincerely, Immune Response BioPharma Legal Department
Saturday, June 18, 2011
Immune Response Corporation and Orchestra Therapeutics, Inc.
The Immune Response Corporation announced on April 16, 2007 that it was changing its name to Orchestra Therapeutics, Inc. The company annunced the rebranding as an effort to reflect expanded focus on Treatment of Autoimmune Disease. The company also annouced that it was terminating its HIV clinical trials to focus fully on its autoimmune program. The company's lead immune-based therapeutic product candidate is NeuroVax(TM) for the treatment of MS.
Thursday, June 16, 2011
Immune Response Corporation
One of the early disasters for Immune Response (IMNR) later Orchestra Therapeutics (OCHTQ.PK) occurred in December of 2000. A report surfaced that the biotechnology company tried to block publication of a major AIDS study that found that the experimental treatment the company was developing failed to improve the health of patients, the scientists conducting the research said. An article by Scott Gottlieb in Vaccines and Microbicides said that "The Immune Response company of Carlsbad, California, opposed publication of the study because it did not include a subanalysis it believed showed that the treatment boosted the immune system of some patients. But despite the objections of the company, the researchers, led by James Kahn of the University of California at San Francisco, submitted their results to JAMA, which published them."
The researchers reported that the study of 2527 patients at 77 hospitals tested the vaccine marketed under the name Remune and concluded that it failed to show any advantage in survival or in slowing the progression of Aids. "In September the vaccine's manufacturer refused to provide all the study data to Dr. Kahn and his colleagues, and Dr. Kahn refused to put what the company wanted in the paper. Dr. Kahn and his colleagues felt that the information that the company wished to include was "data dredging" which investors took to be an attempt by the company to hide or manipulate the negative test results.
The bad publicity the dispute between the company and the scientists conducting their research proved very damaging to the companies reputation.
The researchers reported that the study of 2527 patients at 77 hospitals tested the vaccine marketed under the name Remune and concluded that it failed to show any advantage in survival or in slowing the progression of Aids. "In September the vaccine's manufacturer refused to provide all the study data to Dr. Kahn and his colleagues, and Dr. Kahn refused to put what the company wanted in the paper. Dr. Kahn and his colleagues felt that the information that the company wished to include was "data dredging" which investors took to be an attempt by the company to hide or manipulate the negative test results.
The bad publicity the dispute between the company and the scientists conducting their research proved very damaging to the companies reputation.
Wednesday, June 15, 2011
Immune Response BioPharma
I invested in a company called Immune Response Corporation (IMNR) many years ago after learning that my sister and a close friend had both been diagnosed with Rheumatoid arthritis. Immune Response was started in 1986 by Kevin Kimberlin and Jonas Salk the inventor of the Polio vaccine. The company was originally formed in response to the Aids epidemic and later branched out into other research such as rheumatoid arthritis. The company's main focus was on their Aids vaccine called REMUNE and IR103 which they claimed stabilized CD4+ Cell Counts In Drug-Naive HIV patients. In early 2007 the company began trails of a new drug called NeuroVax(TM) for Treatment of Multiple Sclerosis. The company invested thousands of hours of research along with millions of dollars in hopes of bringing a product to market. The company was first met on Wall Street with great enthusiasm with its connection to the renowned Joans Salk. The company entered into a partnership agreement with Pfizer and was developing the aids drug with a unit of Pfizer called Agouron Pharmaceuticals. The company's spokesperson Kathy Lane gave regular updates on the progress of the companies research and investors and sufferers of the various diseases they were researching had great hope.
Gradually hope and the stock price began to fall as the companies research trails continued to return failing results. In July 2001 shares for the stock were cut in half after Pfizer announced they were terminating a partnership to develop Remune's AIDS vaccine. Basically, observers noted that the companies research trails had been so poorly designed and administered that even what little positive results they achieved could not be trusted by the scientific community. The companies shares plunged as investors and employees of the company cut their losses and moved on.
In attempts to stay on the NASDAX the company reversed stock prices twice and changed their name to Orchestra Therapeutics (OCHT) in hopes of luring in more investors to stay afloat. The companies co-founder Kevin Kimberlin through Spencer Trask began giving operating money to the company in return for ownership of the companies intellectual property rights until the company finally filed Chapter 7.
A new company then emerged called Immune Response Biopharma led by David Buswell. This company claims that the research and intellectual property rights of the stock holders and Kevin Kimberlin were abandoned and that they have now claimed legal ownership. Immune Response Biopharma is seeking to issue an IPO using the Immune/Orchestra research. A spokesperson for Immune Response Biopharma said that what they are attempting to market and develop was essentially left in the trash.
Gradually hope and the stock price began to fall as the companies research trails continued to return failing results. In July 2001 shares for the stock were cut in half after Pfizer announced they were terminating a partnership to develop Remune's AIDS vaccine. Basically, observers noted that the companies research trails had been so poorly designed and administered that even what little positive results they achieved could not be trusted by the scientific community. The companies shares plunged as investors and employees of the company cut their losses and moved on.
In attempts to stay on the NASDAX the company reversed stock prices twice and changed their name to Orchestra Therapeutics (OCHT) in hopes of luring in more investors to stay afloat. The companies co-founder Kevin Kimberlin through Spencer Trask began giving operating money to the company in return for ownership of the companies intellectual property rights until the company finally filed Chapter 7.
A new company then emerged called Immune Response Biopharma led by David Buswell. This company claims that the research and intellectual property rights of the stock holders and Kevin Kimberlin were abandoned and that they have now claimed legal ownership. Immune Response Biopharma is seeking to issue an IPO using the Immune/Orchestra research. A spokesperson for Immune Response Biopharma said that what they are attempting to market and develop was essentially left in the trash.
Tuesday, June 14, 2011
Immune Response BioPharma and Immune Response Corporation and Orchestra Therapeutics, Inc. Kevin Kimberlin, & Spencer Trask
This blog is concerning a new company recently formed by a David Buswell called Immune Response BioPharma and this companies use of the research begun in 1988 by Kevin Kimberlin and Jonas Salk in a company called the Immune Response Corporation (IMNR) (now Orchestra Therapeutics, Inc.). This company now trades under the symbol OCHTQ.PK. David Buswell and Immune Response BioPharma are now laying claims to the research conducted by Immune Response/Orchestra saying that the research has been abandoned though stockholders in the company still hold, buy and sell stock in the compnay and have not relinquished any of their rights. Immune Response BioPharma plans on issuing stock through an IPO offering though they say that the research they are basing their company on was found in the "trash." This blog is being written by a long time stock holder in IMNR/OCHT who wishes to defend his rights as a stock holder and investor who financed the research that David Buswell and company are now trying to market. I also wish to inform others as to the history and connection of Immune Response BioPharma to Immune Response Corporation and Orchestra Therapeutics, Inc.
Subscribe to:
Posts (Atom)